Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Stock Scheduled to Reverse Split on Friday, July 31st

Shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) are going to reverse split on Friday, July 31st. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, July 30th.

Calidi Biotherapeutics Price Performance

Shares of CLDI opened at $0.10 on Monday. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.15. The company’s fifty day simple moving average is $0.16 and its 200 day simple moving average is $0.42. Calidi Biotherapeutics has a 1-year low of $0.10 and a 1-year high of $10.92. The company has a market cap of $1.93 million, a price-to-earnings ratio of -0.02 and a beta of 1.30.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Calidi Biotherapeutics

Hedge funds have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in Calidi Biotherapeutics during the fourth quarter worth about $25,000. DRW Securities LLC bought a new stake in Calidi Biotherapeutics in the fourth quarter valued at approximately $173,000. Finally, Geode Capital Management LLC lifted its position in shares of Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after buying an additional 12,334 shares during the last quarter. 12.53% of the stock is currently owned by institutional investors and hedge funds.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.